Chinese authorities are investigating allegations that Chinese executives at GSK were involved in passing bribes to boost sales.
The highest honors went to the teams that defended the Affordable Care Act and prosecuted the companies involved in the Deepwater Horizon oil rig disaster.
The baby formula maker said it is complying with the Securities and Exchange Commission’s request and has opened an internal investigation.
The British drugmaker nevertheless says it is “committed” to China, which is “critical” to its future.
A Chinese newspaper reported today that the eye care division had paid doctors in more than 200 hospitals for phony clinical trials.
Dumex, the baby food brand owned by France’s Danone, said on Monday it was investigating allegations on Chinese state television that the company bribed doctors and nurses to recommend its infant formula to the parents of newborns at some hospitals.
China has launched a high-profile campaign against purported corruption among foreign pharmaceutical companies this summer. UPDATED
Expanding the investigation to include the China allegations is a routine step.
U.K. laws could prevent it from pursuing a case against one of its own companies if Chinese and U.S. authorities have gotten there first.
It’s not just rouge employees to blame, the official Xinhua news agency reported.
Gelfand has been a partner at Cleary, Gottlieb, Steen & Hamilton LLP handling antitrust litigation since 1997.
Chinese authorities have recently brought intense pressure to bear on foreign drug makers over alleged bribery.
Company directors won plaudits for the acquisition of a Chinese drug maker in 2011 but the outcome has been less rosy than it may originally have seemed.
At the moment, then, there are (at least) four investigations by Chinese authorities into foreign companies: Baxter, Sanofi, GSK and AstraZeneca.
Restrictions in the flow of background information could potentially leave foreign investors exposed to greater risk in the world’s second-largest economy.
If GSK isn’t the only pharmaceutical company under investigation by Chinese authorities, a look to the list of drug makers whose conduct in China has also been probed by the United States may offer clues to the others.
GlaxoSmithKline first revealed it was under U.S. scrutiny in an October 21, 2010 6-K filing with the SEC.
Chinese authorities have detained four GSK executives on bribery allegations in a notably aggressive crackdown on the British pharmaceutical company.
Chinese officials on Monday released new details of their bribery allegations against GlaxoSmithKline PLC and said that four executives have been detained, intensifying a probe into the drug maker.
U.K. drug maker GlaxoSmithKline PLC is investigating allegations that sales personnel in China rewarded doctors with cash and perks for prescribing Botox, and allegedly tried to cover their tracks by using private email, as part of a broader probe into allegations of bribery that date back several years.
The report expressed dissatisfaction with British efforts to combat white-collar crime, particularly by major British banks which have faced much stiffer penalties in the U.S. than they have in their home jurisdiction.
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing.
Pharmaceutical giant GlaxoSmithKline’s massive health care fraud settlement made the list, too.
The 94 federal prosecuting offices across the country returned more than six times their operating budgets to the U.S. Treasury through collection of fines and penalties.
Officials noted a focus on financial fraud and health care fraud.
Bradley Birkenfeld’s lawyers say they believe it is the largest whistleblower award ever, though the IRS won’t confirm.
Just Anti-Corruption has learned that the British anti-fraud agency is prepared to move against the Eurasian Natural Resources Corporation, in headlines in Britain over corruption allegations. But it has not pulled the trigger.
The Great Britain-based drugmaker admitted to introducing misbranded drugs and failing to report safety data.
Is the biggest corruption vs. anti-corruption drama a long, long way from the Rio Grande?
Lawyers in several high-profile prosecutions last year explained their strategies at the American Bar Association’s white collar crime meeting in Miami last week.
"He certainly comes at the law from a prosecutor's perspective." -- William Yeomans on DOJ official Roy Austin, the leading candidate to head ICE.